{"analyses":[{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"97.38","ciUpperLimit":"0.91","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0052","paramType":"Cox Proportional Hazard","paramValue":"0.63","statisticalComment":"Stratified by PD-L1 (≥ 1% vs \\<1%/unevaluable/indeterminate), disease stage (IB/II vs IIIA), and sex (male vs female)","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.03","upperLimit":"26.71","value":"20.80"},{"comment":"Insufficient number of participants with events","groupId":"OG001","lowerLimit":"30.16","upperLimit":"NA","value":"31.57"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"Event-free survival (EFS) is defined as the length of time from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on blinded independent central review (BICR) assessment per response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days).\n\nFollowing definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.","id":"OG000","title":"Arm B: Platinum Doublet Chemo"},{"description":"Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days).\n\nFollowing definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.","id":"OG001","title":"Arm C: Nivo 360 mg + Platinum Doublet Chemo"}],"paramType":"MEDIAN","populationDescription":"All concurrently randomized participants in Arm C and Arm B","reportingStatus":"POSTED","timeFrame":"From randomization to disease progression, reoccurrence, or death due to any cause. (Up to a median of 30 months)","title":"Event-Free Survival (EFS)","type":"PRIMARY","unitOfMeasure":"Months"}